Nordion, Inc.

Nordion, Inc. provides vital medical isotopes and radiation-based solutions, emphasizing Cobalt-60 for cancer treatment, sterilization, and food safety applications, thereby supporting healthcare and industrial sectors globally. Founded in 1946 in Ottawa, Canada, Nordion, Inc. specializes in medical isotopes, playing a crucial role in healthcare through the supply of Cobalt-60.

The company was taken private by SteriGenics International for USD 826 mn in March 2014, a strategic shift enhancing its operational focus. The current CEO is Dipak Wankhede. Nordion specializes in the production and supply of medical isotopes and radiation-based solutions, focusing on Cobalt-60, which is used in cancer therapy, sterilization of medical devices, and food irradiation. The company’s gamma irradiation systems serve a diverse clientele, including hospitals and food processing sectors, primarily across North America, Europe, and Asia.

Nordion aims to improve global health outcomes through its isotope supply, ensuring high safety and efficacy standards in addressing pressing healthcare needs. In 2014, Nordion reported a revenue of USD 232. 80 mn and an EBITDA of USD 34. 20 mn.

The company's revenue largely stems from the sale and service of Cobalt-60 products and irradiation solutions, structured through long-term contracts with healthcare and industrial clients, bolstered by tailored service agreements that include technological support and customer training. Nordion is focused on expanding its product offerings and geographic reach, particularly targeting emerging markets in Asia and Europe for growth by 2025. The recent funding of USD 826 mn will be allocated towards developing new irradiation technologies and enhancing its service capabilities to meet increasing demand. Additionally, Nordion aims to introduce advanced Cobalt-60 applications to improve patient outcomes and expand its industrial service sector.